HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $2.5 Price Target

Benzinga · 10/09 18:41
HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $2.5 price target.